Ramipril Capsule
Product Images NDC 51655-406

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 406 52)

Label (51655 406 52)
The given text seems to be a mix of some medicine-related information and some random text including "Keep g of e resch of chiren." which is not understandable. The medicine-related information includes the NDC (National Drug Code) and the name of the medicine - Ramipril, in the form of capsules with a strength of 10 mg.*
FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)
This appears to be a graph or chart showing the proportion of patients taking Ramipril over time with days of follow-up on the X-axis and the proportion of patients on the Y-axis. Without additional context, it is difficult to determine the exact meaning or significance of the data points shown.*
FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)
This appears to be a table with different categories and numbers related to cardiovascular disease, diabetes, hypertension, and other medical conditions. The table also mentions a placebo group and a Ramipril group, but it is not clear what the numbers mean without additional context.*
FDA Label Image

Chemical Structure (Ramipril Str)

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.